Cargando…
Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin
Community-acquired pneumonia (CAP) is the cause of substantial morbidity, mortality, and resource utilization worldwide. When choosing an antimicrobial, effective treatment depends on proper patient evaluation and the identification of numerous risk factors, such as recent antibiotic exposure or the...
Autor principal: | Öncü, Serkan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386358/ https://www.ncbi.nlm.nih.gov/pubmed/18488076 |
Ejemplares similares
-
Biphasic anaphylaxis to gemifloxacin
por: Yilmaz, İnsu, et al.
Publicado: (2012) -
Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia
por: Amitabh, Vindu, et al.
Publicado: (2012) -
Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis
por: Jivcu, Cristian, et al.
Publicado: (2009) -
Immunomodulatory activities of gemifloxacin in mice
por: Umair, Muhammad, et al.
Publicado: (2016) -
Clinical Effects of Gemifloxacin on the Delay of Tuberculosis Treatment
por: Kim, Seo Yun, et al.
Publicado: (2013)